Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Axitinib plus pembrolizumab in advanced RCC

Michael Atkins • 26 May 2020
ASCO 2020
Genitourinary Cancer Kidney Cancer Axitinib Pembrolizumab

Michael Atkins, MD, of Georgetown University, Washington, DC, reports long-term efficacy and safety from a phase Ib study investigating the combination of axitinib and pembrolizumab in advanced renal cell carcinoma patients. This video was recorded via an online conference call with the Video Journal of Oncology (VJOncology).

More from Michael Atkins

1:46
Clinical trials in kidney cancer to look out for
Michael Atkins • 17 Feb 2023
1:34
Potential new biomarkers for advanced ccRCC treatment response identified
Michael Atkins • 17 Feb 2023
6:16
Treatment-free survival results of nivolumab and salvage nivolumab + ipilimumab for accRCC
Michael Atkins • 17 Feb 2023
1:44
TIVO-3: tivozanib hydrochloride vs sorafenib for refractory advanced RCC
Michael Atkins • 18 Feb 2022

Related Videos

2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals